Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Study of Standard Systemic Therapy in Treating Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
In order to participate you must meet the following criteria:
- Have histologically or cytologically proven diagnosis of adenocarcinoma of the prostate.
- Have an intact prostate.
- Have received no more than 28 weeks of standard systemic therapy (SST).
This is a partial list of elgibility requirements.